OCUMENSION-B (01477) announced its financial results for the year ended December 31, 2025. The group recorded revenue of 804 million yuan, representing a year-on-year increase of 92.75%. The annual loss was 159 million yuan, a decrease of 40.8% compared to the previous year. The loss per share was 0.2 yuan.

The company continued to expand its presence in the hospital market, with sales of its main products maintaining steady growth. Its core product, YUTIQ® (fluocinolone acetonide intravitreal implant), continues to play a key role in its growth strategy. BEOVU® (aflibercept injection) received approval from the National Medical Products Administration (NMPA) for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) in adults, marking the introduction of another important product in the company's portfolio for retinal diseases.

The significant revenue growth was primarily driven by a substantial increase in sales of ophthalmic products, including Xalatan®, Eysuvis®, and products acquired and licensed from Alcon as part of the Alcon transaction. Additionally, there was a notable rise in sales-based royalty income, largely fueled by the successful commercialization of BEOVU®.